134 related articles for article (PubMed ID: 2021339)
1. Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival.
Barth RJ; Danforth DN; Venzon DJ; Straus KL; d'Angelo T; Merino MJ; Gerber L
Arch Surg; 1991 May; 126(5):574-7. PubMed ID: 2021339
[TBL] [Abstract][Full Text] [Related]
2. Complete axillary lymph node dissection for stage I-II carcinoma of the breast.
Danforth DN; Findlay PA; McDonald HD; Lippman ME; Reichert CM; d'Angelo T; Gorrell CR; Gerber NL; Lichter AS; Rosenberg SA
J Clin Oncol; 1986 May; 4(5):655-62. PubMed ID: 3701387
[TBL] [Abstract][Full Text] [Related]
3. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
5. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
6. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
Rouzier R; Extra JM; Klijanienko J; Falcou MC; Asselain B; Vincent-Salomon A; Vielh P; Bourstyn E
J Clin Oncol; 2002 Mar; 20(5):1304-10. PubMed ID: 11870173
[TBL] [Abstract][Full Text] [Related]
7. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
8. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
9. Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India.
Joshi S; Noronha J; Hawaldar R; Kundgulwar G; Vanmali V; Parmar V; Nair N; Shet T; Badwe R
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30811304
[TBL] [Abstract][Full Text] [Related]
10. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
11. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
12. The correlation between the spread of metastases by level in the axillary nodes and disease-free survival in breast cancer. A multifactorial analysis.
Gaglia P; Bussone R; Caldarola B; Lai M; Jayme A; Caldarola L
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):849-54. PubMed ID: 3653201
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Alagol H
Eur J Surg Oncol; 2003 Dec; 29(10):839-44. PubMed ID: 14624774
[TBL] [Abstract][Full Text] [Related]
14. Axillary lymph node involvement in stage III breast cancer: treatment implications.
Voss M; Schneider JW; Apffelstaedt J
J Surg Oncol; 1999 Jul; 71(3):162-6. PubMed ID: 10404132
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
18. Reappraisal of internal mammary node metastases as a prognostic factor in patients with breast cancer.
Noguchi M; Ohta N; Koyasaki N; Taniya T; Miyazaki I; Mizukami Y
Cancer; 1991 Nov; 68(9):1918-25. PubMed ID: 1655229
[TBL] [Abstract][Full Text] [Related]
19. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients.
Saha S; Farrar WB; Young DC; Ferrara JJ; Burak WE
J Surg Oncol; 2000 Mar; 73(3):134-7. PubMed ID: 10738265
[TBL] [Abstract][Full Text] [Related]
20. [Lobular invasive breast cancer prognostic factors: About 940 patients].
Jauffret C; Houvenaeghel G; Classe JM; Garbay JR; Giard S; Charitansky H; Cohen M; Bélichard C; Faure C; Darai É; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Goncalves A; Lambaudie É
Gynecol Obstet Fertil; 2015 Nov; 43(11):712-7. PubMed ID: 26482833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
